Medicine and Dentistry
Bacilli
13%
Biological Marker
11%
Biopsy
16%
Bladder
42%
Bladder Cancer
70%
Bladder Tumor
12%
Cancer Specific Survival
13%
Cisplatin
20%
Clear Cell Renal Cell Carcinoma
38%
Clinical Trial
19%
Cystectomy
100%
Disease
37%
Gemcitabine
13%
Glomerular Filtration Rate
13%
Hazard Ratio
28%
Immunotherapy
10%
Ischemia
11%
Kidney Cancer
9%
Kidney Function
16%
Kidney Tumour
16%
Lymph Node
19%
Malignant Neoplasm
50%
Metastatic Carcinoma
14%
Muscle Invasive Bladder Cancer
45%
Neoadjuvant Chemotherapy
27%
Neobladder
13%
Neoplasm
64%
Nephroureterectomy
20%
Non Muscle Invasive Bladder Cancer
23%
Overall Survival
37%
Partial Nephrectomy
38%
Pelvis
14%
Penile Cancer
9%
Programmed Death-Ligand 1
10%
Proportional Hazards Model
12%
Prostate Cancer
32%
Quality of Life
9%
Radical Nephrectomy
15%
Recurrence Free Survival
15%
Recurrent Disease
30%
Retroperitoneal Lymph Node Dissection
15%
Surgeon
9%
Surgery
11%
Systematic Review
11%
Transitional Cell Carcinoma
62%
Transurethral Resection
9%
Urinary Diversion
25%
Urinary System
9%
Urology
11%
Urothelial Cancer
26%
Keyphrases
Bacillus Calmette
12%
Black Men
12%
Bladder
20%
Bladder Cancer
82%
Bladder Tumor
15%
Cancer Genome Atlas
9%
Cancer Patients
12%
Cancer-specific Survival
15%
Cisplatin
10%
Clear Cell Renal Cell Carcinoma (ccRCC)
16%
Clinical Trials
17%
Complication Rate
10%
Confidence Interval
28%
Cystectomy
31%
Estimated Glomerular Filtration Rate
10%
Functional Outcome
12%
Gemcitabine
12%
Genitourinary Cancer
10%
Genomic Characterization
10%
Hazard Ratio
28%
High Risk
13%
Intracorporeal Urinary Diversion
13%
Metastatic Urothelial Cancer
10%
Multivariable
14%
Muscle-invasive
9%
Muscle-invasive Bladder Cancer
42%
National Cancer Database
19%
Natural Killer Cells
13%
Neoadjuvant Chemotherapy
25%
Nephroureterectomy
18%
Non-muscle Invasive Bladder Cancer (NMIBC)
34%
Oncological Outcomes
17%
Overall Survival
35%
Partial Nephrectomy
14%
PD-1 Blockade
11%
Phase II Trial
11%
Postoperative Outcomes
18%
Programmed Death-ligand 1 (PD-L1)
12%
Prostate Cancer
17%
Radical Cystectomy
42%
Radical Nephrectomy
10%
Recurrence-free Survival
18%
Renal Cell Carcinoma
25%
Robot-assisted Partial Nephrectomy
14%
Robot-assisted Radical Cystectomy
38%
Tumor
35%
Tumor Microenvironment
11%
Upper Tract Urothelial Carcinoma
67%
Urinary Diversion
11%
Urothelial Cancer
16%